Lebrikizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atopic Dermatitis
Conditions
Atopic Dermatitis
Trial Timeline
Feb 3, 2020 → Sep 16, 2021
NCT ID
NCT04250337About Lebrikizumab
Lebrikizumab is a phase 3 stage product being developed by Eli Lilly for Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04250337. Target conditions include Atopic Dermatitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07006792 | Approved | Recruiting |
| NCT05372419 | Phase 3 | Completed |
| NCT05369403 | Phase 3 | Completed |
| NCT04840901 | Phase 1 | Completed |
| NCT04392154 | Phase 3 | Completed |
| NCT04250350 | Phase 3 | Completed |
| NCT04250337 | Phase 3 | Completed |
| NCT04178967 | Phase 3 | Completed |
| NCT04146363 | Phase 3 | Completed |
Competing Products
20 competing products in Atopic Dermatitis